Download PDF
Thromb Haemost 1997; 78(02): 803-807
DOI: 10.1055/s-0038-1657632
Rapid Communication
Schattauer GmbH Stuttgart

A 6-month Venographic Follow-up in 164 Patients with Acute Deep Vein Thrombosis

Margareta Holmström
1   The Department of Haematology, Karoiinska Hospital, Stockholm, Sweden
,
Per Lindmarker
2   The Department of Internal Medicine, Karoiinska Hospital, Stockholm, Sweden
,
Staffan Granqvist
3   The Department of Radiology,Huddinge Hospital, Stockholm, Sweden
,
Hans Johnsson
2   The Department of Internal Medicine, Karoiinska Hospital, Stockholm, Sweden
,
Dieter Lockner
1   The Department of Haematology, Karoiinska Hospital, Stockholm, Sweden
› Author Affiliations
Further Information

Publication History

Received 01 1996

Accepted after resubmission 07 April 1997

Publication Date:
12 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

A total of 164 patients were recruited from a randomized trial comparing a low molecular weight heparin, dalteparin, given subcutaneously once daily with a continuous intravenous infusion of unfractionated heparin in the initial treatment of acute deep vein thrombosis. The primary objective of this follow-up study was to investigate whether there were any differences between the two treatment groups with respect to Marder score changes 6 months after the initial diagnosis using repeated venography. The secondary objectives were to analyse whether certain haemostatic and acute phase parameters or patient characteristics influenced the venographic outcome. Results: Complete lysis of the thrombus was observed in 38.4% of the patients and a partial lysis in another 54.3% assessed by venography 6 months after the acute event. Extension of the thrombus was seen in 7.3% of the patients. There were no significant differences in the change in mean Marder score before treatment and at the 6 month follow-up between the two treatment groups, irrespective of thrombus localisation. In a regression model, male gender, low levels of orosomucoid and increased levels of d-di- mer in plasma on day 5 were independently associated (p <0.05) with an enhanced absolute resolution of the thrombus at 6 months. No differences in symptoms and signs in the thrombotic leg at follow-up, comparing the treatment given, or thrombus extension at diagnosis and 6 months later, were demonstrated. Conclusion: Dalteparin given once daily subcutaneously was as effective as continuous intravenous infusion of unfractionated heparin in the initial treatment of deep vein thrombosis assessed by Marder score evaluation 6 months after the acute event.

 

  • References

  • 1 Leizorovicz A, Simonneau G, Decousus A, Boissel JP. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in the initial treatment of deep venous thrombosis: a meta-analysis. BMJ 1994; 309: 299-304
    CrossrefPubMedSearch in Google Scholar
  • 2 Lockner D. Low molecular weight heparin for treatment of established venous thromboembolism. In: Low molecular weight heparin in prophylaxis and therapy of thromboembolic disease. Bounameaux H. ed. Marcel Dekker Inc.; Basel: 1995: 283-305
    Search in Google Scholar
  • 3 ten CateJW, Koopman M, Prins M, Büller HR. Treatment of venous thromboembolism. Thromb Haemost 1995; 75 (01) 197-203
    Thieme ConnectPubMedSearch in Google Scholar
  • 4 Holm HA, Ly B, Handeland GF, Abildgaard U, Amesen KE, Gottschalk P, Hoeg V, Aandahl M, Haugen K, Laerum F, Scheel B, Sortland O, Vinje B. Subcutaneous heparin treatment of deep venous thrombosis with low molecular weight heparin. Haemostasis 1986; 16 (Suppl. 02) 30-37
    PubMedSearch in Google Scholar
  • 5 Prandoni P, Lensing AWA, Büller HR, Carta M, Cogo A, Vigo M, Casara D, Ruol A, ten CateJW. Comparison of subcutaneous low-molecular weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992; 339: 441-445
    CrossrefPubMedSearch in Google Scholar
  • 6 Lindmarker P, Holmstrom M, Granqvist S, Johnsson H, Lockner D. Comparison of once-daily subcutaneous Fragmin® with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1994; 72: 186-190
    Thieme ConnectPubMedSearch in Google Scholar
  • 7 Duroux P, Beclere A. A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis: A collaborative European multicentre study. Thromb Haemost 1991; 65: 251-256
    Thieme ConnectPubMedSearch in Google Scholar
  • 8 Bratt G, Tomebohm E, Granquist S, Åberg W, Lockner D. A comparison between low molecular weight heparin (KABI2165) and standard heparin in the treatment of deep venous thrombosis. Thromb Haemost 1985; 54: 813-817
    Thieme ConnectPubMedSearch in Google Scholar
  • 9 Bratt G, Åberg W, Johansson M, Tömebohm E, Granquist S, Lockner D. Two daily subcutaneous injections of Fragmin® compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT). Thromb Haemost 1990; 64: 506-510
    Thieme ConnectPubMedSearch in Google Scholar
  • 10 Common H, Seaman A, Rösch J, Porter J, Dotter C. Deep vein thrombosis treated with streptokinase or heparin. Angiology 1976; 27: 645-654
    CrossrefPubMedSearch in Google Scholar
  • 11 Elliot M, Immelman P, Jeffery P, Benatar R, Funston M, Smith B, Shepstone J, Ferguson D, Jacobs P, Walker W, Louw J. A comparative randomized trial of heparin versus streptokinase in the treatment of acute proximal venous thrombosis: an interim report of a prospective trial. Br J Surg 1979; 66: 838-843
    CrossrefPubMedSearch in Google Scholar
  • 12 Isacsson S, Nilsson IM. Defective fibrinolysis in blood and vein walls in recurrent idiopathic venous thrombosis. Acta Chir Scand 1972; 138: 313-319
    PubMedSearch in Google Scholar
  • 13 Conard J, Veuillet-Duval A, Horellou MH, Samama M. Etude de la coagulation et de la fibrinolyse dans 131 cas de thromboses vineuses récidivantes. Nouvelle Revue Francaise d′Uématologie 1982; 24: 205-209
    PubMedSearch in Google Scholar
  • 14 Schulman S, Wiman B. and the DURAC Trial Study Group. The significance of hypofibrinolysis for the risk of recurrence of venous thromboembolism. Thromb Haemost 1996; 75: 607-611
    Thieme ConnectPubMedSearch in Google Scholar
  • 15 Rabinov K, Paulin S. Roentgen diagnosis of venous thrombosis in the leg. Arch Surg 1972; 104: 134-144
    CrossrefPubMedSearch in Google Scholar
  • 16 Marder VJ, Soulen RL, Atichartakam V, Budzynski AZ, Parulekar S, Kim JR, Edward N, Zahavi J, Algazy KM. Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy. J Lab Clin Med 1977; 89: 1118-1129
    PubMedSearch in Google Scholar
  • 17 Marsh NA, Minter AJ, Chesterman CN. The effect of heparin and other glycosaminoglycans on levels of tissue plasminogen activator and plasminogen activator inhibitor in cultured human umbilical vein endothelial cells. Blood Coag and Fibrinolysis 1990; 1: 133-138
    PubMedSearch in Google Scholar
  • 18 Grulich-Henn J, Preissner KT, Miiller-Berghaus G. Heparin stimulates fibrinolysis in mesothelial cells by selective induction of tissue-plasminogen activator but not plasminogen activator inhibitor-1 synthesis. Thromb Haemost 1990; 64: 420-425
    Thieme ConnectPubMedSearch in Google Scholar
  • 19 Chmielewska J, Wiman B. Determination of tissue plasminogen activator and its “fast” inhibitor in plasma. Clin Chem 1986; 32: 482-485
    PubMedSearch in Google Scholar
  • 20 Jansson J-H, Norberg B, Nilsson TK. Impact of acute phase on concentrations of tissue plasminogen activator and plasminogen activator inhibitor in plasma after deep-vein thrombosis or open-heart surgery. Clin Chem 1989; 35: 1544-1545
    PubMedSearch in Google Scholar
  • 21 The DVTenox study group. Markers of the hemostatic system activation in acute deep venous thrombosis-evolution during the first days of heparin treatment. Thromb Haemost 1993; 70: 909-914
    Thieme ConnectPubMedSearch in Google Scholar